Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 dose‑ranging study of RO5073031 added to metformin in type 2 diabetes mellitus
2006-004407-19Phase 2Completed
- Sponsor
- Roche
- Start
- Nov 2006
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of taspoglutide in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Roche. Primary endpoint: Change in HbA1c from baseline. Started Nov 2006; status: completed.
02
Drugs
taspoglutide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2006-004407-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-004407-19.